title: [The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of metastatic renal cell carcinoma].
abstract: We prospectively investigated the safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) in 24 patients (22 males, 2 females ; age range 39-86 years, median 64 years) with metastatic renal cell carcinoma (RCC). During the observation period (3-62 weeks, median 21 weeks), thrombocytopenia was seen in 13 (54.2%), leukopenia in 11 (45.8%), hand-foot syndrome in 5 (20.8%), hypertension in 4 (16.7%), and hypothyroidism in 3 (12.5%) patients, while grade 3 or higher adverse events were found in 4 (16.7%), 1 (4.2%), 1 (4.2%), 2 (8.3%), and 0 patients, respectively. Of the 21 patients evaluable for response, 5 (23. 8%) showed partial response, 8 (38.1%) stable disease, and 8 (38.1%) progressive disease. This new modified regimen may lead to a reduction in adverse events for treatment of patients with metastatic RCC as a substitute for the standard dosing regimen of sunitinib.
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Togo
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Kimihiro
authors.initials: K
authors.lastname: Shimatani
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Hanasaki
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Toeki
authors.initials: T
authors.lastname: Yo
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Yukako
authors.initials: Y
authors.lastname: Nakanishi
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Seiji
authors.initials: S
authors.lastname: Nagasawa
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Takahiko
authors.initials: T
authors.lastname: Hashimoto
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Shiraishi
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Rikiya
authors.initials: R
authors.lastname: Taoka
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Toru
authors.initials: T
authors.lastname: Suzuki
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Shuken
authors.initials: S
authors.lastname: Go
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Higuchi
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Kanematsu
authors.affiliation: The Department of Urology, Hyogo College of Medicine.
authors.forename: Michio
authors.initials: M
authors.lastname: Nojima
authors.affiliation: The Department of Urology, Nishi Kobe Medical Center.
authors.forename: Kazunari
authors.initials: K
authors.lastname: Tsuchihashi
authors.affiliation: The Department of Urology, Nishi Kobe Medical Center.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Makino
authors.affiliation: The Department of Urology, Nishi Kobe Medical Center.
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Shimizu
authors.affiliation: The Department of Urology, Nishi Kobe Medical Center.
authors.forename: Sojun
authors.initials: S
authors.lastname: Kanamaru
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Kono
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Keiyu
authors.initials: K
authors.lastname: Matsumoto
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Noriaki
authors.initials: N
authors.lastname: Utsunomiya
authors.affiliation: The Department of Urology, Nishi Kobe Medical Center.
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Ito
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Mutsushi
authors.initials: M
authors.lastname: Kawakita
authors.affiliation: The Department of Urology, Hyogo College Of Medicine.
authors.forename: Shingo
authors.initials: S
authors.lastname: Yamamoto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011446:Prospective Studies; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib